title: A randomized, multicenter study comparing the efficacy of recombinant FSH vs recombinant FSH with Ganirelix during superovulation/IUI therapy.
abstract: OBJECTIVE
  The purpose of this study was to determine if use of a Gonadotropin releasing hormone (GnRH) antagonist, Ganirelix (Antagon), can improve pregnancy rates during superovulation with recombinant follicle-stimulating hormone (rFSH) followed by intrauterine insemination (IUI).
  
  
  METHODS
  This was a multicenter, prospective, randomized, open-label, assessor-blind, controlled trial of females (n = 54), ages 18 to 39 undergoing superovulation/IUI with up to 4 cycles of superovulation/IUI without Ganirelix (n = 66), or up to 4 cycles of superovulation/IUI with the addition of Ganirelix (n = 52).
  
  
  RESULTS
  No statistically significant difference in clinical pregnancy rates per cycle initiated was found for patients in the treatment or control group (12% vs 7%, P =.29). Other variables assessed, including endometrial thickness, size of follicles, peak serum estradiol levels, mid-lutea progesterone levels, and total vials of rFSH used also showed no statistically significant difference.
  
  
  CONCLUSIONS
  Superovulation/IUI cycles using Ganirelix produce similar pregnancy rates when compared with cycles not using a GnRH antagonist, although there is a trend towards better pregnancy rates in cycles with Ganirelix.
authors.affiliation: Department of Obstetrics and Gynecology, University of Florida, Gainesville, FL 32607, USA. Williams@obgyn.ufl.edu
authors.forename: R Stan
authors.initials: RS
authors.lastname: Williams
authors.forename: Jessica B
authors.initials: JB
authors.lastname: Hillard
authors.forename: Gary
authors.initials: G
authors.lastname: De Vane
authors.forename: Tim
authors.initials: T
authors.lastname: Yeko
authors.forename: Simon
authors.initials: S
authors.lastname: Kipersztok
authors.forename: Alice
authors.initials: A
authors.lastname: Rhoton-Vlasak
authors.forename: Chris
authors.initials: C
authors.lastname: Sistrom
mesh_terms: D000328:Adult; D004359:Drug Therapy, Combination; D005260:Female; D043373:Follicle Stimulating Hormone, Human / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000627:therapeutic use*; D006801:Humans; D007247:Infertility, Female / Q000628:therapy*; D007315:Insemination, Artificial / Q000379:methods*; D011247:Pregnancy; D011256:Pregnancy Outcome; D018873:Pregnancy Rate; D013480:Superovulation; D016896:Treatment Outcome
chemical_list: D043373:Follicle Stimulating Hormone, Human; D007987:Gonadotropin-Releasing Hormone; C061018:ganirelix